OPDIVO® (nivolumab) OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) to treat adults with a type of liver cancer called hepatocellular carcinoma (HCC) when your liver cancer cannot be removed by surgery or has spread, and you have received prior treatment with sorafenib
Advanced PD-L1 Positive NSCLC - OPDIVO See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1
Financial Information: Cost, Access Affordability - OPDIVO Important Facts About OPDIVO® (nivolumab) and OPDIVO + YERVOY® (ipilimumab) This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY Your healthcare team can work with you to help answer any questions you may have about these medications
Frequently Asked Questions (FAQ) | OPDIVO® (nivolumab) Find answers to frequently asked questions about OPDIVO® (nivolumab) including what OPDIVO® is, how immunotherapy works, and what are the side effects of OPDIVO®
OPDIVO® Support Patient Resources | OPDIVO® (nivolumab) Whether you're a new or continuing OPDIVO® (nivolumab) patient, find resources that can support you through a cancer diagnosis and during treatment Access helpful resources and find assistance for OPDIVO® patients here
Advanced Kidney Cancer | Clinical Trial Results | OPDIVO® (nivolumab . . . OPDIVO ® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC